Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of antipsychotic polypharmacy to monotherapy in schizophrenia
NL-OMON32961Phase 4Recruiting
- Sponsor
- Symforagroep
- Start
- Apr 2010
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in schizophrenia and Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Symforagroep. Primary endpoint: Relapse. Started Apr 2010; status: recruiting.
02
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON32961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32961.